Intravenous therapies for castration-resistant prostate cancer: Toxicities and adverse events - Abstract

Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.


Prostate cancer (CaP) continues to be a significant burden on men's health. While significant advances have been made in the diagnosis and treatment of localized disease, androgen deprivation therapy remains the treatment of choice for advanced and metastatic disease. However, once a man progresses on androgen deprivation, therapies targeting castration-resistant CaP have been extremely limited until quite recently. Urologic oncologists who wish to play an active role in the treatment of men with CaP from diagnosis through end-of-life care should be familiar with administration of and toxicities associated with chemotherapeutic agents. This review is directed at urologists and urologic oncologists and will discuss many of the FDA-approved intravenous agents currently available for castration-resistant CaP with a specific focus on the side-effects associated with these regimens.

Written by:
Singer EA, Srinivasan R.   Are you the author?

Reference: Urol Oncol. 2011 Oct 17. Epub ahead of print.
doi: 10.1016/j.urolonc.2011.09.003

PubMed Abstract
PMID: 22014836 Prostate Cancer Section